Phenethyl isothiocyanate and dasatinib combination synergistically reduces hepatocellular carcinoma growth via cell cycle arrest and oxeiptosis

Phenethyl isothiocyanate and dasatinib combination synergistically reduces hepatocellular carcinoma growth via cell cycle arrest and oxeiptosis

Introduction: Hepatocellular carcinoma (HCC) is the most common type of liver cancer, which is among the most lethal tumours. Combination therapy exploits multiple drugs to target key pathways synergistically to reduce tumour growth. Isothiocyanates have been shown to possess anticancer potential an...

Full description

Bibliographic Details
Main Authors: Gabriele Strusi, Caterina M. Suelzu, Nicole Horwood, Andrea E. Münsterberg, Yongping Bao
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-10-01
Series:Frontiers in Pharmacology
Subjects:
cancer therapeutics
oncology
drug development
oxeiptosis
combination therapy
dasatinib
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2023.1264032/full

Internet

https://www.frontiersin.org/articles/10.3389/fphar.2023.1264032/full

Similar Items